All posts by medical

The Real Reason Some ‘Grey’s Anatomy’ Fans Can’t Stand Catherine Fox – Showbiz Cheat Sheet

Greys Anatomy has graced our televisions for nearly 15 years and over 350 episodes, and theres no sign of an ending in sight. Greys Anatomy has featured over 100 different characters over the course of the series, so its no surprise that it is more divisive than others.

While many internet commenters have recently targeted Richard Webber, its his wife that has been drawing the internets ire for years and years. Since Catherine Foxs first appearance in season 8, fans have argued online (and off) about whether her measured business acumen and her ruthless drive for success are traits of a villain or just a strong personality.

Back in July 2017, fans had already begun to turn on Catherine as seen in this string of Reddit comments(some strong language).

However, things have slowly shifted. Whether its a sign of a well-written character developing another dimension or simply a pushback in the culture of 2019 against casual sexism, more fans have come to Catherines defense when arguments start to fly. A recent Reddit post describing her as the worst parts of Owen and Bailey (and incorrectly referring to her as CatherineAvery) quickly found quickly saw Catherines defenders piling on.

Incorrect and short sighted, user svargs01 replied. Catherine Fox (she changed her name, recognize it) is a powerful woman who knows the limits of her gender during her time and knows when she needs to step on peoples toes to get what she wants and when to hang back and let the boys talk it out.

Surprisingly, this actually led to a worthwhile discussion among users. There is certainly some sexism in the dislike for Catherine Fox, as many of her more controversial acts would have been more accepted if a man had performed them.

However, Catherines gender isnt a shield that absolves her from all the blame, as her cover-up of Harper Averys sexual assaults was the wrong thing to do, as noble as her goal to preserve the foundation was. Her decisions (and subsequent renaming of the foundation) didnt bring the justice the victims deserved, but she maintained the ability of the foundation to do good.

Since she joined the show, Catherine has driven much of the action. Regardless of the internets opinion on her, her presence makes Greys Anatomy a much stronger show. Fans have leveled criticism at the show that after fifteen seasons the writers are falling into tired old tropes. Characters make showsand strong characters are necessary for good TV.

When Catherine was diagnosed with cancer, Greys fans were united in their desire to see her survive, love her or hate her. This isnt the reaction fans would have for a real villain who was actively fighting against the good guys of the show.

Knowing that Catherine is imperfect (as everyone but Meredith is, it seems), it becomes easier to critically examine the internets dislike for her. Every action hasnt been perfectly good, but (male) characters who have done far worse have received a warmer response.

Catherine Foxs actions have never been from a place of spite or jealousy, never out of hate or malice. When she crosses the line and does something controversial (such as covering up Harper Averys actions) its to protect something goodin this case, a legacy that has changed lives.

Any reasonable analysis of her dislike will find that at least some of it are rooted in sexism, even if shes not perfect. Men in her position would have accomplished less and received more praise for it. Theres no one in theShondaverse exactly like Catherine Fox, and Catherine wouldnt have it any other way.

Original post:
The Real Reason Some 'Grey's Anatomy' Fans Can't Stand Catherine Fox - Showbiz Cheat Sheet

‘Grey’s Anatomy’ Season 16: When Will the Latest Season Drop on Netflix? – Showbiz Cheat Sheet

Viewers are half-way through Greys Anatomy season 16 and patiently awaiting the midseason premiere. In the meantime, fans would love to rewatch the first half of the season. Lets take a look at when viewers can expect to stream season 16 on Netflix.

Over the past 16 years, Greys Anatomy fans went through many character changes. Two of the most devastating departures on the show were that of Cristina Yang (Sandra Oh) and Derek Shepherd (Patrick Dempsey).

Cristina bid farewell to Meredith Grey (Ellen Pompeo) during the season 10 finale when she moved to Zurich, Switzerland to further her career aspirations. Dereks shocking death occurred during season 11 when he was hit by a semi-truck. When he was rushed to the local ER, the surgeon refused to perform a head CT scan, which ultimately led to his death.

Izzie Stevens (Catherine Heigl) concluded her run on the show when she left during season six after Alex Karev (Justin Chambers) refused to continue their marriage.

George O Malley (T. R. Knight) tragically died at the end of season five after he was hit by a bus. His fellow surgeons worked on him in the ER, but did not realize it was their beloved friend until it was too late.

The only original cast members that remain on Greys Anatomy in season 16 are Meredith Grey, Alex Karev, Miranda Bailey (Chandra Wilson) and Richard Webber (James Pickens, Jr.) All four have said they will continue the show until the end.

With 16 seasons, many viewers ask if the show will ever come to an end. The series is still one of the most popular primetime shows on American television. It is now the longest-running American primetime scripted medical drama, surpassing ER, Scrubs, and M*A*S*H.

On May 10, 2019, Greys Anatomy was renewed for seasons 16 and 17. Both Shonda Rhimes and Pompeo agree that they will stop doing the show when they both agree.

The show is so popular, Pompeo toldEllen Degeneresin October 2018. Everywhere I go, whether its Italy, whether its France, London, Kansas the people that come up to me with tears in their eyes and tell me how meaningful the show is to them.

I got to keep doing it, man, because were touching lives and making a difference, she continued. Pompeo sees no end in sight for the medical drama.

The season finale of Greys Anatomy typically occurs in mid-May. Then, the entire season drops on Netflix about one month later.

The 15th season of Greys Anatomy came to Netflix on June 15, 2019, almost exactly one month after the season finale on May 16, 2019.

We expect the season 16 finale around May 14, 2020. Then all episodes of season 16 will arrive to Netflix about one month later around June 14, 2020.

In the meantime, viewers can watch the first 15 seasons of Greys Anatomy on Netflix. The season 16 midseason premiere is Jan. 23, 2020. The series returns to its original time slot on ABC9 p.m.following the spinoff, Station 19.

View original post here:
'Grey's Anatomy' Season 16: When Will the Latest Season Drop on Netflix? - Showbiz Cheat Sheet

When Will Greys Anatomy Season 16 Premiere On Netflix? Heres Every Detail Of It – The Digital Weekly

The arrangement has experienced numerous progressions

Darks Anatomy has been a dominant power on the US organise ABC and keeps on being one of the most well known primetime appears on American TV. The arrangement has experienced numerous progressions in the course of the last fifteen seasons, yet one staying consistent has been Ellen Pompeo featuring Meredith Gray.

The record-breaking arrangement keeps on crushing them out of the recreation centre, going into the sixteenth season. Not exclusively is Grays Anatomy the longest-running scripted primetime conveyed by ABC, yet it is likewise the longest-running American primetime restorative show arrangement, surpassing ER, Scrubs, and M*A*S*H.

Regularly, the most recent seasons of Greys Anatomy arrive in the late spring on Netflix. The fifteenth season went ahead of the fifteenth of June, very nearly one month after the finale had circulated on ABC.

According to earlier years, the arrangement is set to wrap up on ABC come May 2020. We anticipate that the finale of season sixteen should land toward the finish of April or the beginning of May. Netflix ought to get season sixteen about a month after the finale pretence.

Fans will be enchanted to realise that Grays Anatomywas restored for two further seasons on May tenth, 2019. The arrangement was restored for seasons 16 and 17, with lead on-screen character Ellen Pompeo broadening her agreement for two additional seasons.

Whats to come of Greys Anatomy beyond season 17 stays a puzzle. Review figures for the fifteenth season took a plunge contrasted with past seasons. The prevalence of the arrangement is as yet extraordinary after such a long time; however, all useful things must conclude in the end.

See the original post here:
When Will Greys Anatomy Season 16 Premiere On Netflix? Heres Every Detail Of It - The Digital Weekly

Augmedics Announces FDA 510K Clearance and US Launch of xvision, the First Augmented Reality Guidance System for Surgery – BioSpace

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191223005111/en/

The xvision consists of a transparent near-eye-display headset and all elements of a traditional navigation system. It accurately determines the position of surgical tools, in real time, and a virtual trajectory is then superimposed on the patient's CT data. The 3D navigation data is then projected onto the surgeons retina using the headset, allowing him or her to simultaneously look at the patient and see the navigation data without averting his or her eyes to a remote screen during the procedure. The system is designed to revolutionize how surgery is done by giving the surgeon better control and visualization, which may lead to easier, faster and safer surgeries.

Augmedics successfully completed a percutaneous laboratory study with the xvision Spine at Rush University Medical Center with investigators Frank Phillips, M.D., Camilo Molina, M.D., Kornelis Poelstra, M.D., Ph.D., Larry Khoo, M.D., and Matthew Colman, M.D. Ninety-three screws were positioned in the thoracic and sacro-lumbar areas of five different cadavers. The study was conducted as evidence to the FDA to evaluate the accuracy of the xvision Spine system by comparing the actual screw tip position and trajectory versus the virtual. The result of overall clinical accuracy, analyzed by two independent neuro-radiologists, was 98.9 percent using the Heary (thoracic) and Gertzbein (lumbar) scales. This study adds to the evidence of accuracy and usability found last year in another cadaver study performed by two surgeons from Johns Hopkins Medicine, Daniel Sciubba, M.D., and Timothy Witham, M.D., one surgeon from Sheba Tel-Hashomer, Israel, Ran Harel, M.D., and one from Assaf Harofeh, Israel, Yigal Mirovsky. The study last year was conducted at Vista Labs, an independent lab in Baltimore, with results published in the Journal of Neurosurgery: Spine.

The ability that Augmedics xvision provides to visualize the patients spinal anatomy in 3D, coupled with live CT images as a retina display, is game changing, said Frank Phillips, M.D., Professor of Orthopaedic Surgery, Rush University Medical Center. The efficiency and accuracy this augmented reality technology enables in placing spinal implants without looking away from the surgical field - as well as the ability to "see the spine" through the skin in minimally invasive procedures - differentiates the xvision from conventional spinal navigation platforms. The economics of the xvision system are also compelling in both the hospital and the surgicenter environment.

Augmedics mission is to give surgeons more control by creating technological advances that cater to their needs and fit within their workflow, said Nissan Elimelech, founder and CEO of Augmedics. xvision is our first product of many to follow that will revolutionize surgery, as it gives surgeons the information they need, directly within their working field of sight, to instill technological confidence in the surgical workflow and help them do their jobs as effectively and safely as possible.

xvision is now available for sale in the United States, with headset distribution expected to begin in early 2020. Augmedics plans to explore additional surgical applications for xvision beyond spinal surgery. The systems small footprint, economical cost and compatibility with current instrumentation is designed to allow easy integration into any surgical facility nationwide.

About Augmedics

With Augmedics, the future of surgery is within sight. The Chicago-based company aims to improve healthcare by augmenting surgery with cutting edge technologies that solve unmet clinical needs and instill technological confidence in the surgical workflow. Its pioneering xvision system, the first augmented reality guidance system for surgery, allows surgeons to see the patients anatomy through skin and tissue as if they have x-ray vision, and to accurately navigate instruments and implants during spine procedures. Augmedics is backed by Terra Venture Partners and AO Invest, a venture arm of the AO Foundation. The AO is a medically guided, not-for-profit organization, a global network of surgeons, and the world's leading education, innovation, and research organization for the surgical treatment of trauma and musculoskeletal disorders. For more information, visit http://www.augmedics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191223005111/en/

Go here to read the rest:
Augmedics Announces FDA 510K Clearance and US Launch of xvision, the First Augmented Reality Guidance System for Surgery - BioSpace

25 Celebrities You Forgot Guest Starred on ‘Grey’s Anatomy’ – Just Jared

Thu, 19 December 2019 at 12:00 pm

Next Slide

Before many of your favorite stars became household names they were on Greys Anatomy.

The beloved ABC series has been on the air since since 2005 almost 15 years and is currently in its 16th season.

Stars like Demi Lovato, Millie Bobby Brown, and Mandy Moore have all made cameos on the show.

Weve rounded up 25 celebrities whom you might have forgotten had guest-starring roles.

Season 16 of Greys Anatomy returns on January 23!

READ MORE: Ellen Pompeo Reveals Her Ideal Ending for Greys Anatomy!

Click through the slideshow to see which celebs you forgot guest starred on Greys Anatomy

Read the rest here:
25 Celebrities You Forgot Guest Starred on 'Grey's Anatomy' - Just Jared

DNA Tests Make a Fun Gift But Here’s What You Need to Know Before You Unwrap – ScienceAlert

You've likely heard about direct-to-consumer DNA testing kits. In the past few years, at-home genetic testing has been featured in the lyrics of chart-topping songs, and has helped police solve decades-old cold cases, including identifying the Golden State Killer in California.

Even if you don't find a DNA testing kit under your own Christmas tree, there's a good chance someone you know will.

Whether you're motivated to learn about your health or where your ancestors came from, it is important to understand how these tests work - before you spit in the tube.

While exciting, there are things that these genetic testing kits cannot tell users - and important personal implications that consumers should consider.

My main area of research is around clinical genome sequencing, where we look through all of a person's DNA to help diagnose diseases. With a PhD in genetics, I often get questions from friends and family about which direct-to-consumer genetic test they should buy, or requests to discuss results. Most questions are about two types of products: ancestry and health kits.

The most popular ancestry kit is from AncestryDNA. These kits are aimed at giving users insight into where their ancestors might be from. They can also connect users with family members who have used the service and have opted into having their information shared.

Another option is Living DNA, which has a smaller dataset but provides more precise information on the UK and Ireland.

The most popular health kit is from 23andMe. Depending on the user's preference, results include information on predispositions for diseases such as diabetes and Alzheimer's, as well as on the likelihood of having certain traits such as hair colour and taste.

This company also offers ancestry analysis, as well as ancestry and trait-only kits that don't provide health information. The kit offered by the newer MyHeritage DNA also provides a combined ancestry and health option.

There are other kits out there claiming to evaluate everything from athletic potential to relationship compatibility. But gift-buyers beware: for most of these, in contrast to those above, the evidence is seriously lacking.

A direct-to-consumer DNA testing kit. (Shutterstock)

For all of these tests, customers receive a kit in the mail. The kits contain instructions for collecting a saliva sample, which you mail back to the company for analysis.

During this analysis, these popular tests do not look at the entire genome. Instead, they employ single nucleotide polymorphism (SNP) genotyping. As humans we all share 99.9 per cent of our DNA. SNPs are essentially what is left: all of the points at which we can differ from our neighbour, making us unique. SNP genotyping looks at a subset of these sites to "survey" the user's genome.

These SNPs are then compared to reference datasets of individuals with known conditions or ancestry. Most results are based on the SNPs shared with a given group.

For example, if your results say that you are 42 per cent Southeast Asian, it's because 42 per cent of your SNPs were most likely to have come from a group in the reference dataset labelled "Southeast Asian." The same goes for traits and health conditions.

Direct-to-consumer genetic tests are not a substitute for clinical assessment. The methods used differ dramatically from what is done to diagnose genetic diseases.

In a clinical setting, when suspicion of a genetic condition is high, entire genes are often analyzed. These are genes where we understand how changes in the DNA cause cellular changes that can cause the disease. Furthermore, clinical assessment includes genetic counselling that is often key to understanding results.

In contrast, findings from direct-to-consumer genetic tests are often just statistical links; there is commonly no direct disease-causing effect from the SNPs.

Users may interpret a result as positive, when the risk increase is only minimal, or entirely false. These tests can also give false reassurance because they do not sequence genes in their entirety and can miss potentially harmful variants.

These tests are exciting: they introduce new audiences to genetics and get people thinking about their health. They're also helping to build vast genetic databases from which medical research will be conducted.

But for individual users, there are important caveats to consider. Recent reports have questioned the accuracy of these tests: identical twins can receive different results. Furthermore, a lack of diversity in the reference data has caused particular concern regarding accuracy of results for ethnic minorities.

There are also concerns about the way these tests emphasize racial categories that science considers to be social constructs and biologically meaningless.

A recent paper in the British Medical Journal suggests four helpful questions for users to consider. First, users should ask themselves why they want the test. If it is to answer a medical question, then they should speak with their doctor. Users should also think about how they might feel when they receive results containing information they would rather not know.

Users should also consider issues around security and privacy. It is important to read the fine print of the service you're using, and determine whether you're comfortable sharing personal information, now and in the future.

In Canada, policies around genetics have not always kept up with the science. At present, direct-to-consumer genetic testing is unregulated. And, although Canadians have legislative protections against genetic discrimination, those laws are being challenged in the courts, and could change.

Finally, it may also be worth discussing DNA testing with relatives. We share half of our genome with our immediate family members, and smaller fractions with more distant relatives. Genetic results not only affect us, but our family.

Some users may feel they learn more about themselves. For others, results may bring people closer together - not a bad outcome for the holiday season.

At the end of the day, these genetic testing kits are for entertainment: they should not be used to assess health risk in any meaningful way.

If you have any questions related to your health or a genetic disease, discuss these with your family doctor or a suitable health-care professional.

Michael Mackley, Junior Fellow, MacEachen Institute for Public Policy and Governance; Medical Student, Dalhousie University.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more from the original source:
DNA Tests Make a Fun Gift But Here's What You Need to Know Before You Unwrap - ScienceAlert

Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive…

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tucatinib. This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least three prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting. The submission is based on the results of HER2CLIMB, a randomized pivotal trial comparing tucatinib added to trastuzumab and capecitabine versus trastuzumab and capecitabine alone. HER2CLIMB trial results were presented on December 11, 2019 at the 2019 San Antonio Breast Cancer Symposium and published in the New England Journal of Medicine. Tucatinib is an oral, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2.

Tucatinib was recently granted Breakthrough Therapy designation by the FDA in combination with trastuzumab and capecitabine, for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have been treated with trastuzumab, pertuzumab, and T-DM1. This designation was based on data from the HER2CLIMB trial.

Todays submission marks another important milestone for Seattle Genetics and tucatinib, and a potential advance for patients with either locally advanced or metastatic HER2-positive breast cancer, including those with and without brain metastases, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. We look forward to working with the FDA on the review of this application.

About HER2-Positive Breast Cancer

Patients with HER2-positive breast cancer have tumors with high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the aggressive spread of cancer cells. An estimated 271,270 new cases of invasive breast cancer will be diagnosed in the U.S. in 2019.1 Between 15 and 20 percent of breast cancer cases worldwide are HER2-positive.2 Historically, HER2-positive breast cancer tends to be more aggressive and more likely to recur than HER2-negative breast cancer.2, 3, 4 In patients with metastatic breast cancer, the most common site of first metastasis is in bone, followed by lung, brain, and liver.5, 6 Up to 50 percent of metastatic HER2-positive breast cancer patients develop brain metastases over time.2, 7 Despite recent treatment advances, there is still a significant need for new therapies that can impact metastatic disease, especially brain metastases. There are currently no approved therapies demonstrating progression-free survival or overall survival benefit for the treatment of patients with HER2-positive metastatic breast cancer after progression on T-DM1.8, 9, 10

About HER2CLIMB

HER2CLIMB is a multinational randomized (2:1), double-blind, placebo-controlled, active comparator, pivotal clinical trial comparing tucatinib in combination with trastuzumab and capecitabine compared with trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer who were previously treated with trastuzumab, pertuzumab, and T-DM1. The primary endpoint of the trial was PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by blinded independent central review (BICR) in the first 480 patients enrolled in the trial. HER2CLIMB enrolled a total of 612 patients to support the analyses of key secondary endpoints, including overall survival, PFS per BICR in patients with brain metastases at baseline, and confirmed objective response rate. Safety data were evaluated throughout the study.

About Tucatinib

Tucatinib is an investigational, orally bioavailable, potent tyrosine kinase inhibitor that is highly selective for HER2 without significant inhibition of EGFR. Inhibition of EGFR has been associated with significant toxicities, including skin rash and diarrhea. Tucatinib has shown activity as a single agent and in combination with both chemotherapy and other HER2 targeted agents such as trastuzumab.1, 2 Studies of tucatinib in these combinations have shown activity both systemically and in brain metastases. HER2 is a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. HER2 mediates cell growth, differentiation, and survival. Tucatinib has been granted orphan drug designation by the FDA for the treatment of breast cancer patients with brain metastases.

In addition to HER2CLIMB, tucatinib is being evaluated in a randomized, double-blind, placebo-controlled, multi-center phase 3 trial of tucatinib in combination with T-DM1 compared to T-DM1 alone, in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, who have had prior treatment with a taxane and trastuzumab. The primary endpoint is progression-free survival per RECIST criteria. Secondary endpoints include overall survival, objective response rate, and duration of response. The trial is being conducted in North America and is expected to enroll approximately 460 patients. More information about the phase 3 trial, including enrolling centers, is available at http://www.clinicaltrials.gov.

Tucatinib is also being evaluated in a multi-center, open-label, single-arm phase 2 clinical trial known as MOUNTAINEER, which is evaluating tucatinib in combination with trastuzumab in patients with HER2-positive, RAS wildtype metastatic, or unresectable colorectal cancer. The primary endpoint of the trial is objective response rate by RECIST criteria. Progression-free survival, duration of response, overall survival, and safety and tolerability of the combination regimen are secondary objectives. Results for 26 patients were evaluated in an analysis and presented at the European Society for Medical Oncology (ESMO) 2019 Congress. Enrollment is ongoing. More information about the MOUNTAINEER trial, including enrolling centers, is available at http://www.clinicaltrials.gov.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops, and commercializes transformative medicines targeting cancer to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) use the companys industry-leading antibody-drug conjugate (ADC) technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer, and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland, and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least three prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting; the therapeutic potential of tucatinib, including its possible efficacy, safety and therapeutic uses and anticipated development activities including ongoing and future clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the possibility that the New Drug Application submission based on the HER2CLIMB trial may not be accepted for filing by, or ultimately approved by, the FDA in a timely manner or at all or with the requested label; the difficulty and uncertainty of pharmaceutical product development; the risk of adverse events or safety signals; and the possibility of disappointing results in ongoing or future clinical trials despite earlier promising clinical results. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

References:

View original post here:
Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive...

The technique, physiology and painkillers behind James Anderson’s longevity as 150th Test looms – The Telegraph

Bowling a cricket ball fast is essentially an exercise in contorting the human body into an unnatural and often painful shape, then delivering the ball with enough pace, accuracy and movement to try and get the batsman out. In Test cricket history, no pace bowler has undergone this task more than James Anderson. He has already delivered 32,359 balls, a number that will mushroom further from Boxing Day.

In Centurion, Anderson will become the ninth cricketer to play 150 Test matches. It is, most obviously, a testament to his multifarious skills. But it is, too, a testament to how Anderson, and England, have managed his body. In some ways this is the most remarkable part of Andersons career: simply...

Here is the original post:
The technique, physiology and painkillers behind James Anderson's longevity as 150th Test looms - The Telegraph

PhysIQ Named One of the Most Innovative Companies of 2019 by PM360 – Business Wire

CHICAGO--(BUSINESS WIRE)--PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named physIQ as one of the most innovative Companies of 2019.

PhysIQs mission is to deliver on the promise of scalable personalized medicine by applying artificial intelligence to data collected from any wearable biosensor and transforming it into personalized insight. The physIQ solution provides clinicians with tools to proactively engage at-risk patients, as well as provide pharmaceutical companies with powerful data-driven support to demonstrate the efficacy of their products.

Using an AI-based approach to personalized physiology analytics, physIQ has been clinically validated, with multiple market-leading 510(k) clearances that include respiration rate, QRS detection, heart rate, heart rate variability, atrial fibrillation detection, and our personalized physiology change detection analytic.

Previously, physicians and clinical trial sponsors were limited in monitoring ambulatory patients with noisy and very sporadic point-measurement data. PhysIQ enables them to collect high quality continuous data to gain better insights and make better decisions for their patients, said physIQs CEO Gary Conkright. With physIQ, pharmaceutical companies will now have greater clarity on the impact clinical trials have on patients, allowing for new life saving therapies to reach the market faster. As a result, physicians will have a better chance to care for their patients in their own homes at the lowest possible cost while delivering the highest quality of life.

PhysIQ was selected as part of PM360s 8th Annual Innovations Issue published each December. This issue was established to serve as a guide to the years most innovative Companies, Startups, Divisions, Products, Services, and Strategies from within the healthcare and life sciences industries. This comprehensive overview of the years most innovative achievements in these six categories helps other companies in the industry to find potential partners and offerings that can help them advance healthcare and life sciences.

For the past eight years, we have worked to help the industry identify the latest and most exciting advancements that facilitate change in the industry, how it operates, or offer new advancements that better serve patients, doctors, payers, and others involved, says Anna Stashower, CEO/Publisher of PM360. We hope this guide can serve as an important resource for the industry throughout 2020 as we all work to improve the healthcare experience for everyone involved.

PM360 received hundreds of submissions from across the healthcare and life sciences industries. The editorial staff of PM360 evaluated each submission and selected their picks for the most innovative, regardless of category. Ultimately, 60 total innovations were featured in the issue. Within the Company category, a total of 12 companies were featured.

All of this years selections can be found at: http://www.pm360online.com/pm360-presents-the-2019-innovators.

About physIQ

PhysIQ is a company dedicated to enabling proactive care delivery models through pinpointIQ, its highly scalable cloud-based platform for personalized physiology analytics. Our FDA 510(k)-cleared data analytics platform is designed to process multiple vital signs from wearable sensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships this way, physIQs analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health. With applications in both healthcare and clinical trial support, physIQ is transforming continuous physiological data into insight for providers, health systems, payers and pharmaceutical and medical device companies. For more information, please visit http://www.physIQ.com. Follow us on Twitter and LinkedIn.

About PM360

PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.

The journals targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the 360 in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.

By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.

Read the original:
PhysIQ Named One of the Most Innovative Companies of 2019 by PM360 - Business Wire

Who was the man behind Pavlovs Dog? – Russia Beyond

Ivan Pavlov might be Russias most famous scientist, but for most foreigners he lives in the shadow of his famous experiments with dogs. But who was Pavlov, and what else did he contribute to the history of science?

Im told that the denizens of Koltushi, nestled just twenty kilometers outside St. Petersburg, are little aware of who planted the trees in the towns beloved park. Im there on a Saturday, and many are taking a stroll with family or friends. My guide, Irina Aktuganova, continues that not many would know that the wooden buildings scattered through the greenery form part of the regions UNESCO-protected heritage, an extended monument to Russias most famous scientist and first Nobel Laureate: Ivan Petrovich Pavlov.

When foreigners think of Ivan Pavlov, theyre more likely to think of his experiments with dogs than the parks he cultivated. In fact, they might not even think about the man at all a strange fate for a scientist whose name appears in high school textbooks the world over. Little is mentioned of the pond where the aging researcher would swim every morning, or the banya where hed invite guests for a good sweat, or about the beloved bicycle he bought in Sweden before Lenins revolution. Or how he survived the revolution, for that matter.

Ivan Pavlov (second right) in his laboratory. Leningrad, 1927

I had no idea before coming to Koltushi that the same hands that rang bells for dogs also cultivated whole orchards of apple trees, or that young chimpanzees used to clamor here between the trees and busts of scientists like Decartes, Mendel or Sechenov. Aktuganova, the curator of a new permanent exhibition of art and science located in the basement of Pavlovs historical lab, shares that it was the scientist himself who developed this land from a loose hamlet, once inhabited by the Finnish diaspora, into the countrys first official academic village.

Born in 1849 in what was still the Russian Empire, Pavlov was the eldest of eleven children raised by a Russian orthodox priest and his wife. Due to an early injury as a child, he was unable to start school until he was eleven years old. Despite this, he showed a high degree of intelligence and academic potential he was reading independently by the age of seven, and after switching from theology to physiology (moving his studies from Ryazan to St. Petersburg in order to do so) he won prestigious awards while still an undergraduate.

House-museum of academician Ivan Pavlov in the city of Ryazan where he was born

His greatest award, though, was yet to come. After leaving for a stint in Germany to receive his doctorate, he returned to St. Petersburg and was eventually invited to organize the Department of Physiology at the Institute of Experimental Medicine there in 1891, which he would go on to transform into a global center for physiological research. He was nominated for the Nobel Prize in Physiology or Medicine every year after 1901 until winning it in 1904, not for his work with dogs, but in recognition of his work on the physiology of digestion, through which knowledge on vital aspects of the subject has been transformed and enlarged.

It was on this base, however, that his most famous experiment would be made possible.

The conditioned reflexes Pavlov is known for refers to how any organism with a sufficiently developed nervous system can develop special reflexes in response to its environment. To discover this, Pavlov designed soundproof chambers for the dogs to be kept in, where the only stimulus would be some food or the sound of a bell. The bell would be rung before the dog was given meat, and so the animals eventually learned to associate the bell with being fed. Using his experience with the digestive system, Pavlov was able to measure the dogs saliva levels to confirm that, yes, their glands would eventually produce saliva in response to the bell instead of to the sight or smell of food.

Ivan Pavlov watching an experiment with a dog, summer 1934

It was this discovery that led to his becoming a household name. Curiosity, combined with the mystery associated with his experiments, led to his laboratory complex being named the Tower of Silence. It was located in the center of the old imperial capital, on Petrogradsky island, but the forces of history wouldnt necessarily give Pavlov the silence he was looking for. The outbreak of World War I, and the revolution that followed, turned the city into a chaotic scene of disorder and violence.

Russias first scientific village

While Pavlov was open in his criticism of Soviet ideology, his work earned him the respect of none other than Vladimir Lenin. He couldnt work in disorder, Aktuganova tells me, and so, Pavlov wrote Lenin a letter that said give me a place to work in peace, or Ill emigrate. The plan worked, and the scientist received approximately one million rubles worth of gold to relocate his laboratory. With it he chose Koltushi.

He built a complex for experimental medicine and surrounded it with what became Russias first scientific village. This included his lab, a house (that he rarely used), a complex that included a hotel, cafeteria and club, five cottages for workers and, of course, kennels for the dogs, chimpanzees and other animals he worked with. This formed the core of a set of buildings that eventually expanded with the years, until it became a functional suburb of the ever-growing Leningrad (known now as St. Petersburg).

To look at the place now, Aktuganova tells me, you wouldnt think that a world-famous figure used to live here. With the UNESCO status, there should be more tourists and more infrastructure to support them [visiting].

But remembering Pavlov and his contributions wasnt on the highest list of national priorities after his death from pneumonia in 1936, support for the village continued until perestroika in the 1980s. A greater focus was then given to the humanities, which had faced various pressures over the past half century, and money typically invested in the hard sciences was redirected.

Ivan Pavlov in Koltushi, Leningrad Region

That said, a museum still exists here that tells of how Pavlov lived out the last years of his life. There are pictures of him with his wife Serafima, or Sara for short, and their children (two of which sadly died while Pavlov was still alive). Alongside them are photos of international visitors like Niels Bohr and H.G. Wells. Photos with famous local artists, like Ilya Repin, can also be found, confirming the age Pavlov lived in, as a time when art and science were not necessarily competitors. The permanent exhibition in the basement, a collaboration between young artists and scientists, seeks to revitalize this tradition.

Monument to Pavlov and his dog in Koltushi

Asteroids, lunar craters and scientific principles have since been named after him, but its become all too easy to hear about Pavlov without knowing anything about the man himself. That said, these buildings, much like his famous dogs, stand as a legacy that wont soon be forgotten. What remains is a testament to a remarkable scientist who changed the way we think about our behavior, our desires and the other secrets still locked inside our brains.

If using any of Russia Beyond's content, partly or in full, always provide an active hyperlink to the original material.

') }, error: function() { $email.val(''); alert('An unknown error occurred. Try later.'); } }); } }); }; initFormSubmit(); $completeButton.on('click', function (evt) { evt.preventDefault(); evt.window.location.reload(); }); }());

Excerpt from:
Who was the man behind Pavlovs Dog? - Russia Beyond